bromide has been researched along with vilanterol in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cazzola, M; Matera, MG; Rinaldi, B; Rogliani, P | 1 |
| Birk, R; Farrell, C; Hayes, S; Lipson, DA; Mehta, R; Okour, M | 1 |
| Fowler, A; Lee, LA; Peachey, G; Sule, N; Yang, S | 1 |
| Bolotova, EV; Dudnikova, AV; Shulzhenko, LV | 1 |
1 review(s) available for bromide and vilanterol
| Article | Year |
|---|---|
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.
Topics: Benzyl Alcohols; Bromides; Bronchodilator Agents; Chlorobenzenes; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic | 2015 |
2 trial(s) available for bromide and vilanterol
| Article | Year |
|---|---|
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Aged; Androstadienes; Anticonvulsants; Benzyl Alcohols; Bromides; Chlorobenzenes; Drug Combinations; Female; Humans; Male; Middle Aged; Muscarinic Antagonists; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2020 |
Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Topics: Administration, Inhalation; Androstadienes; Asthma; Benzyl Alcohols; Bromides; Chlorobenzenes; Double-Blind Method; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2021 |
1 other study(ies) available for bromide and vilanterol
| Article | Year |
|---|---|
[Experience of using a triple fixed combination in the treatment of patients with chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Benzyl Alcohols; Bromides; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Humans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Treatment Outcome | 2022 |